Neurocrine Biosciences Inc (NBIX) shareholders
Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 12,052,271 | 12.10% | 13G (passive) amendment | Mar 31, 2025 |
| Dodge & Cox | 5,534,624 | 5.60% | 13G (passive) | Mar 31, 2025 |
| JPMorgan Chase & Co. | 5,300,390 | 5.20% | 13G (passive) amendment | Sep 30, 2026 |
| Vanguard Capital Management | 5,257,941 | 5.23% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 5,083,540 | 5.00% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NBIX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,711,607 | 13.49% | $2.31B | +326,000 | 0.03% |
| JPMorgan Chase & Co | 6,398,674 | 6.29% | $1.09B | +956,607 | 0.06% |
| Dodge & Cox | 5,584,707 | 5.49% | $941.22M | +123,670 | 0.49% |
| Vanguard Portfolio Management LLC | 4,974,083 | 4.89% | $838.31M | +247,739 | 0.04% |
| Vanguard Capital Management LLC | 4,545,339 | 4.47% | $766.05M | +33,435 | 0.02% |
| State Street Corp | 4,385,598 | 4.31% | $739.13M | +31,072 | 0.02% |
| Aqr Capital Management LLC | 3,818,037 | 3.76% | $643.47M | −1,120,930 | 0.22% |
| Renaissance Technologies LLC | 2,335,897 | 2.30% | $393.68M | −83,000 | 0.54% |
| Geode Capital Management, LLC | 2,138,777 | 2.10% | $359.61M | +2,105 | 0.02% |
| Two Sigma Investments, LP | 2,076,260 | 2.04% | $349.92M | −984,310 | 0.25% |
| Vestal Point Capital, LP | 1,880,000 | 1.85% | $316.85M | +630,000 | 7.40% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,494,259 | 1.47% | $251.86M | +446 | 0.25% |
| Morgan Stanley | 1,318,607 | 1.30% | $222.23M | +99,411 | 0.01% |
| Rtw Investments, LP | 1,267,925 | 1.25% | $213.69M | +205,853 | 1.82% |
| Northern Trust Corp | 1,259,717 | 1.24% | $212.31M | +16,887 | 0.02% |
| Invesco Ltd. | 1,077,317 | 1.06% | $181.57M | +721,308 | 0.01% |
| Charles Schwab Investment Management Inc | 974,279 | 0.96% | $164.20M | +71,491 | 0.02% |
| Norges Bank | 973,880 | 0.96% | $164.13M | New | 0.02% |
| First Trust Advisors LP | 923,125 | 0.91% | $155.58M | −36,092 | 0.09% |
| Dimensional Fund Advisors LP | 732,877 | 0.72% | $123.53M | +21,115 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 775 | 101M | 99.5% | 147 / 321 | 225 / 63 | 13M | 11M |
| Q1 2026 | 699 | 100M | 98.5% | 84 / 306 | 216 / 110 | 24M | 13M |
| Q4 2025 | 732 | 99M | 97.7% | 139 / 275 | 224 / 41 | 11M | 13M |
| Q3 2025 | 650 | 102M | 100.0% | 121 / 220 | 219 / 50 | 12M | 10M |
| Q2 2025 | 586 | 99M | 97.5% | 78 / 223 | 221 / 70 | 14M | 11M |
| Q1 2025 | 586 | 96M | 94.8% | 75 / 187 | 254 / 83 | 13M | 11M |
| Q4 2024 | 601 | 95M | 93.3% | 113 / 214 | 211 / 74 | 13M | 12M |
| Q3 2024 | 576 | 95M | 93.2% | 71 / 236 | 202 / 84 | 23M | 11M |
| Q2 2024 | 595 | 96M | 94.9% | 80 / 254 | 189 / 68 | 9M | 13M |
| Q1 2024 | 589 | 100M | 98.8% | 90 / 227 | 208 / 49 | 11M | 7M |
| Q4 2023 | 555 | 97M | 95.3% | 94 / 206 | 199 / 43 | 14M | 9M |
| Q3 2023 | 512 | 92M | 90.4% | 90 / 159 | 197 / 30 | 10M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
635 funds held NBIX in Q2 2026, 54% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NBIX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Dodge & Cox Stock Fund | 3,964,000 | 3.90% | $668.07M | 0.56% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF | 3,441,037 | 3.39% | $579.94M | 0.47% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,193,267 | 3.14% | $538.18M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,304,996 | 2.27% | $388.47M | 0.21% | Jun 30, 2026 |
| JPMorgan Growth Advantage Fund | 1,358,475 | 1.34% | $228.95M | 1.02% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,329,829 | 1.31% | $224.12M | 0.48% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,152,825 | 1.13% | $194.29M | 0.20% | Jun 30, 2026 |
| JPMorgan Mid Cap Growth Fund | 1,116,674 | 1.10% | $188.20M | 1.42% | Jun 30, 2026 |
| iShares Biotechnology ETF | 700,051 | 0.69% | $117.98M | 1.30% | Jun 30, 2026 |
| Vanguard Explorer Fund | 637,614 | 0.63% | $106.35M | 0.48% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 618,966 | 0.61% | $104.32M | 0.97% | Jun 30, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 601,519 | 0.59% | $101.38M | 0.90% | Jun 30, 2026 |
| Invesco S&P MidCap Quality ETF | 599,829 | 0.59% | $100.05M | 1.84% | Jul 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 588,847 | 0.58% | $99.24M | 3.53% | Jun 30, 2026 |
| iShares MSCI USA Min Vol Factor ETF | 527,782 | 0.52% | $88.03M | 0.37% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer, Director | 155,010 | 0.15% | Nov 3, 2026 |
| Eiry Roberts | Chief Medical Officer | 51,331 | 0.05% | Nov 5, 2026 |
| Ingrid Delaet | Chief Regulatory Officer | 18,289 | 0.02% | Sep 15, 2026 |
| Darin Lippoldt | Chief Legal Officer | 59,212 | 0.06% | Sep 15, 2026 |
| Eric Benevich | Chief Commercial Officer | 67,297 | 0.07% | Sep 15, 2026 |
| Sanjay Chandru Keswani | Chief Medical Officer | 5,393 | 0.01% | Sep 15, 2026 |
| Jude Onyia | Chief Scientific Officer | 22,647 | 0.02% | Sep 15, 2026 |
| Matt Abernethy | Chief Financial Officer | 42,808 | 0.04% | Sep 15, 2026 |
| Julie Cooke | Chief Human Resources Officer | 24,025 | 0.02% | Sep 15, 2026 |
| David W. Boyer | Chief Corp. Affairs Officer | 8,722 | 0.01% | Sep 15, 2026 |
| Andrew Ratz | Chief Technical Operations Off | 1,018 | 0.00% | Mar 17, 2026 |
| George J. Morrow | Director | 10,386 | 0.01% | Nov 3, 2026 |
| Kevin Charles Gorman | Director | 517,797 | 0.51% | Sep 15, 2026 |
| Stephen A. Sherwin | Director | 14,860 | 0.01% | Sep 3, 2026 |
| Leslie V. Norwalk | Director | 2,430 | 0.00% | Jul 30, 2026 |
| Johanna Mercier | Director | 6,853 | 0.01% | May 29, 2026 |
| Christine A. Poon | Director | 4,753 | 0.00% | May 29, 2026 |
| Shalini Sharp | Director | 4,088 | 0.00% | May 29, 2026 |
| Gary A. Lyons | Director | 122,141 | 0.12% | May 29, 2026 |
| Richard F. Pops | Director | 37,798 | 0.04% | May 29, 2026 |
| William H. Rastetter | Director | 43,678 | 0.04% | May 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| George J. Morrow Director | Nov 3, 2026 | Sale(10b5-1 plan) | −1,300 | $168.53 | $219.09K | 10,386 |
| George J. Morrow Director | Nov 3, 2026 | Sale(10b5-1 plan) | −1,500 | $167.72 | $251.59K | 11,686 |
| George J. Morrow Director | Nov 3, 2026 | Sale(10b5-1 plan) | −1,466 | $166.77 | $244.49K | 13,186 |
| George J. Morrow Director | Nov 3, 2026 | Sale(10b5-1 plan) | −908 | $165.71 | $150.46K | 14,652 |
| George J. Morrow Director | Nov 3, 2026 | Sale(10b5-1 plan) | −1,226 | $164.74 | $201.97K | 15,560 |
| George J. Morrow Director | Nov 3, 2026 | Sale(10b5-1 plan) | −600 | $163.71 | $98.22K | 16,786 |
| George J. Morrow Director | Nov 3, 2026 | Sale(10b5-1 plan) | −100 | $162.05 | $16.21K | 17,386 |
| George J. Morrow Director | Nov 3, 2026 | Sale(10b5-1 plan) | −100 | $158.18 | $15.82K | 17,486 |
| George J. Morrow Director | Nov 3, 2026 | Option exercise | +7,200 | $53.64 | $386.21K | 17,586 |
| George J. Morrow Director | Nov 2, 2026 | Sale(10b5-1 plan) | −1,300 | $146.76 | $190.78K | 10,386 |
| George J. Morrow Director | Nov 2, 2026 | Sale(10b5-1 plan) | −4,300 | $145.86 | $627.19K | 11,686 |
| George J. Morrow Director | Nov 2, 2026 | Sale(10b5-1 plan) | −1,900 | $144.98 | $275.45K | 15,986 |
| George J. Morrow Director | Nov 2, 2026 | Option exercise | +7,500 | $53.64 | $402.30K | 17,886 |
| Kyle Gano Chief Executive Officer, Director | Nov 1, 2026 | Tax withholding | −332 | $146.10 | $48.51K | 155,010 |
| Kyle Gano Chief Executive Officer, Director | Nov 1, 2026 | Option exercise | +614 | – | – | 155,342 |
| George J. Morrow Director | Oct 30, 2026 | Sale(10b5-1 plan) | −300 | $149.00 | $44.70K | 10,386 |
| George J. Morrow Director | Oct 30, 2026 | Option exercise | +300 | $53.64 | $16.09K | 10,686 |
| David W. Boyer Chief Corp. Affairs Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −826 | $157.45 | $130.05K | 8,722 |
| Matt Abernethy Chief Financial Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −2,311 | $157.20 | $363.29K | 42,808 |
| David W. Boyer Chief Corp. Affairs Officer | Sep 11, 2026 | Award | +3,587 | – | – | 11,484 |
| David W. Boyer Chief Corp. Affairs Officer | Sep 11, 2026 | Tax withholding | −1,936 | $156.22 | $302.44K | 9,548 |
| Eric Benevich Chief Commercial Officer | Sep 11, 2026 | Tax withholding | −3,386 | $156.22 | $528.96K | 67,297 |
| Eric Benevich Chief Commercial Officer | Sep 11, 2026 | Award | +6,275 | – | – | 70,683 |
| Matt Abernethy Chief Financial Officer | Sep 11, 2026 | Award | +5,020 | – | – | 47,828 |
| Matt Abernethy Chief Financial Officer | Sep 11, 2026 | Tax withholding | −2,709 | $156.22 | $423.20K | 45,119 |
| Julie Cooke Chief Human Resources Officer | Sep 11, 2026 | Tax withholding | −1,936 | $156.22 | $302.44K | 24,025 |
| Julie Cooke Chief Human Resources Officer | Sep 11, 2026 | Award | +3,587 | – | – | 25,961 |
| Jude Onyia Chief Scientific Officer | Sep 11, 2026 | Tax withholding | −1,936 | $156.22 | $302.44K | 22,647 |
| Jude Onyia Chief Scientific Officer | Sep 11, 2026 | Award | +3,587 | – | – | 24,583 |
| Kyle Gano Chief Executive Officer, Director | Sep 11, 2026 | Tax withholding | −3,386 | $156.22 | $528.96K | 153,880 |
| Kyle Gano Chief Executive Officer, Director | Sep 11, 2026 | Tax withholding | −994 | $156.22 | $155.28K | 154,728 |
| Kyle Gano Chief Executive Officer, Director | Sep 11, 2026 | Award | +1,842 | – | – | 155,722 |
| Kyle Gano Chief Executive Officer, Director | Sep 11, 2026 | Award | +6,275 | – | – | 157,266 |
| Sanjay Chandru Keswani Chief Medical Officer | Sep 11, 2026 | Award | +3,914 | – | – | 5,393 |
| Sanjay Chandru Keswani Chief Medical Officer | Sep 11, 2026 | Tax withholding | −2,112 | $156.22 | $329.94K | 3,281 |
| Kevin Charles Gorman Director | Sep 11, 2026 | Tax withholding | −7,839 | $156.22 | $1.22M | 517,797 |
| Kevin Charles Gorman Director | Sep 11, 2026 | Award | +14,343 | – | – | 525,636 |
| Darin Lippoldt Chief Legal Officer | Sep 11, 2026 | Award | +4,483 | – | – | 59,212 |
| Darin Lippoldt Chief Legal Officer | Sep 11, 2026 | Tax withholding | −2,419 | $156.22 | $377.90K | 56,793 |
| Ingrid Delaet Chief Regulatory Officer | Sep 11, 2026 | Tax withholding | −2,419 | $156.22 | $377.90K | 18,289 |
| Ingrid Delaet Chief Regulatory Officer | Sep 11, 2026 | Award | +4,483 | – | – | 20,708 |
| Eric Benevich Chief Commercial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −2,154 | $154.61 | $333.03K | 64,408 |
| Eric Benevich Chief Commercial Officer | Sep 9, 2026 | Option exercise | +3,194 | $43.24 | $138.11K | 66,562 |
| Stephen A. Sherwin Director | Sep 2, 2026 | Gift | −1,000 | – | – | 14,860 |
| Jude Onyia Chief Scientific Officer | Aug 4, 2026 | Gift | −2,409 | – | – | 20,996 |
| Leslie V. Norwalk Director | Jul 29, 2026 | Option exercise | +842 | $139.43 | $117.40K | 2,430 |
| Leslie V. Norwalk Director | Jul 28, 2026 | Sale(10b5-1 plan) | −1,250 | $182.01 | $227.51K | 1,588 |
| Ingrid Delaet Chief Regulatory Officer | Jul 10, 2026 | Sale(10b5-1 plan) | −4,367 | $181.02 | $790.51K | 16,225 |
| Ingrid Delaet Chief Regulatory Officer | Jul 10, 2026 | Option exercise | +4,367 | $106.02 | $462.99K | 20,592 |
| Darin Lippoldt Chief Legal Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −10,000 | $179.60 | $1.80M | 54,729 |
| Darin Lippoldt Chief Legal Officer | Jul 9, 2026 | Option exercise | +10,000 | $81.49 | $814.90K | 64,729 |
| Ingrid Delaet Chief Regulatory Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −8,433 | $178.72 | $1.51M | 16,225 |
| Ingrid Delaet Chief Regulatory Officer | Jul 9, 2026 | Option exercise | +8,433 | $103.52 | $872.98K | 24,658 |
| Ingrid Delaet Chief Regulatory Officer | Jul 8, 2026 | Option exercise | +2,737 | $103.52 | $283.33K | 18,962 |
| Ingrid Delaet Chief Regulatory Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −2,737 | $178.54 | $488.66K | 16,225 |
| Ingrid Delaet Chief Regulatory Officer | Jul 7, 2026 | Sale(10b5-1 plan) | −3,401 | $178.57 | $607.32K | 16,225 |
| Ingrid Delaet Chief Regulatory Officer | Jul 7, 2026 | Option exercise | +3,401 | $103.52 | $352.07K | 19,626 |
| Darin Lippoldt Chief Legal Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −8,110 | $170.03 | $1.38M | 54,729 |
| Darin Lippoldt Chief Legal Officer | Jun 29, 2026 | Option exercise | +8,110 | $81.49 | $660.88K | 62,839 |
| Darin Lippoldt Chief Legal Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −1,690 | $170.81 | $288.67K | 54,729 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Neurocrine Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 18,292 shares on Oct 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sanjay Chandru Keswani Former Affiliate | Nov 10, 2026 | 53,614 | $8.97M | Nov 10, 2026 | Exercise of Options Under a Registered Plan |
| George J. Morrow Director | Nov 2, 2026 | 14,700 | $2.15M | Nov 2, 2026 | Exercise of Stock Options |
| George J. Morrow Director | Oct 30, 2026 | 300 | $43.91K | Oct 30, 2026 | Exercise of Stock Options |
| David W. Boyer Officer | Sep 14, 2026 | 4,714 | $736.42K | Sep 14, 2026 | Restricted and Performance Stock Units |
| Matthew C Abernethy Officer | Sep 14, 2026 | 2,311 | $361.02K | Sep 14, 2026 | Performance Stock Units |
| Eric Benevich Officer | Sep 9, 2026 | 2,154 | $334.15K | Sep 9, 2026 | Exercise of Stock Options |
| Ingrid Delaet Officer | Jul 10, 2026 | 4,367 | $788.46K | Jul 10, 2026 | Exercise of Stock Options |
| Darin Lippoldt Officer | Jul 9, 2026 | 10,000 | $1.78M | Jul 9, 2026 | Exercise of Stock Options |
| Ingrid Delaet Officer | Jul 7, 2026 | 14,571 | $2.54M | Jul 7, 2026 | Exercise of Stock Options |
| Darin Lippoldt Officer | Jun 29, 2026 | 9,800 | $1.65M | Jun 29, 2026 | Exercise of Stock Options |
| Darin Lippoldt Officer | Jun 26, 2026 | 200 | $32.84K | Jun 26, 2026 | Exercise of Stock Options |
| Stephen A. Sherwin Director | Jun 5, 2026 | 25,000 | $4.18M | Jun 5, 2026 | Exercise of Stock Options |
| Julie Cooke Officer | Jun 2, 2026 | 36,937 | $5.95M | Jun 2, 2026 | Exercise of Stock Options |
| Jude Onyia Officer | Jun 1, 2026 | 11,000 | $1.74M | Jun 1, 2026 | Exercise of Stock Options |
| Ingrid Delaet Officer | May 29, 2026 | 2,261 | $353.60K | May 29, 2026 | Exercise of Stock Options |
Congress trades
2 trades in Neurocrine Biosciences reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Lisa McClain MI09 · spouse | Sold (part) | Jun 17, 2025 | $1K–15K | Aug 13, 2025 57 days late |
| Lisa McClain MI09 · spouse | Bought | Jun 11, 2025 | $1K–15K | Aug 13, 2025 63 days late |
See a number that looks wrong?